Philip Nadeau is a Managing Director and senior biotechnology research analyst at Cowen and Company. He has been at Cowen for 15 years and is responsible for covering approximately 30 biotechnology stocks. Cowen’s biotechnology team has been the top-ranked team in the Greenwich survey for the past two years and Dr. Nadeau has been recognized in The Wall Street Journal’s “Best on the Street” rankings. Prior to joining Cowen, he was a research assistant at Children’s Hospital, Boston. Dr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a PhD in neurobiology from Harvard University.